There is little data comparing the activity and toxicity of donor lymphocyte therapy with granulocyte (G)-CSF-mobilized cells (G-donor lymphocyte infusion (DLI)) with the conventionally collected DLI (C-DLI) after allogeneic blood or marrow transplantation. We retrospectively evaluated 67 patients to compare the efficacy and toxicity of GCSF-mobilized DLI with C-DLI in the treatment of relapse of malignant disease or poor donor engraftment post transplant. We assessed clinical outcomes that may represent the immunological outcome of DLI. The median OS was 210 days (range 3-2436 days), 291 days (range 17-1491 days) in the G-DLI group (15 patients) and 207.5 days (range 3-2436 days) in the C-DLI group (52 patients). The median PFS time was 72 days (range 8-1491 days) in the G-DLI group vs 82 days (range 1-2436 days) in the C-DLI group. Rates of post DLI GVHD and improvement in donor engraftment were similar in the G-DLI and C-DLI groups. We conclude that G-DLI appears to have similar therapeutic activity to that seen with C-DLI, and where such cells are available they may be substituted for conventional donor lymphocytes.
INTRODUCTION
For patients with AML and other hematological malignancies receiving allogeneic BMT, relapse remains the major cause of treatment failure and is associated with a very poor prognosis. 1, 2 The optimal therapy for these relapsed patients has not been defined, as most therapies are of limited utility. Although re-induction chemotherapy may induce remission in about 30-40% of patients, this remission is often of short duration. 3, 4 The demonstration that infusions of lymphocytes from the original marrow donor may eradicate recurrent leukemia after allogeneic BMT without additional chemotherapy provided direct evidence for a GVL effect. 5, 6 Recently, granulocyte (G)-CSF-mobilized progenitors have increasingly supplanted BM as the source of donor cells for transplantation in adults. For all but the lowest risk patients, shortterm results seem superior with G-CSF-mobilized 'stem cells', with recipients experiencing faster hematopoietic recovery, similar incidence of acute (a) GVHD and superior survival relative to marrow. 7, 8 Although data demonstrate a modest increase in chronic GVHD with G-CSF-mobilized hematopoietic stem cells (G-HSC), 9 most investigators find this acceptable in the context of improved results in the short term. The similar incidence of aGVHD may initially seem counterintuitive given that G-HSC contain 410-fold more donor T cells than marrow. There, however, is data to suggest that G-CSF exposure of donors renders donor cells less alloreactive by skewing the T cells toward a Th2 cytokine profile. 10 Thus, G-CSF may be functionally immunosuppressive when used in the context of allogeneic hematopoietic transplantation. This then raises questions regarding the alloreactivity and therapeutic efficacy of G-CSF-mobilized cells relative to resting peripheral blood lymphocytes. Donor lymphocyte infusion (DLI) for treatment of leukemic relapse after allogeneic HSCT was introduced in the early 1990s. [11] [12] [13] Various studies have shown the efficacy of DLI in the treatment of post-transplant relapse of hematological malignancies. C-DLI involves the collection of peripheral blood lymphocytes from the donor after the initial transplanted cell collection. Typically these DLI cells are collected after post-transplantation relapse has been identified.
Two groups have published analyses suggesting improved results following transplantation with G-HSC when total numbers of CD34-expressing donor cells are limited to 5 Â 10 6 cells/patient/kg body weight (BW). 14, 15 For this reason some centers, including our own, have opted to limit the transplant infusion to that number or less for some patients. Thus for many transplant recipients, excess cells have been cryopreserved and are subsequently available for infusion. Accordingly at our center, a number of patients with post-transplant relapse of malignancy or incomplete donor engraftment have received infusions of the same G-CSF-mobilized stem cells in lieu of conventionally collected donor lymphocytes. There is, however, limited published data comparing the efficacy and toxicity of G-CSFmobilized cells with the conventionally mobilized DLI. In this retrospective study, we evaluated 67 patients to compare the efficacy and toxicity of GCSF-mobilized DLI with C-DLI. Here, we assess various clinical outcomes that may represent the immunological outcome of DLI.
METHODS
With Institutional Review Board approval we performed a systematic, retrospective review of medical charts of all patients who received DLIs at the Penn State Milton S. Hershey Cancer Institute between 1998 and February 2009. We identified 67 patients and reviewed records, thus all had 412 months for follow-up from the initial DLI. OS was calculated from the time of last DLI until death from any cause or last follow-up. PFS was calculated from the day DLI was infused until relapse, death or last followup. GVHD and improvements in chimerism in patients with incomplete engraftment were also studied as outcomes. Factors that were examined for an association with these outcomes included HLA-match grade (that is, matched vs incompletely matched for HLA A, B, C, DR or at the highest available resolution of typing for these loci), number of CD3 þ cells infused, use of immunosuppressive medication at time of DLI, administration of chemotherapy in the 90 days before DLI and DLI with G-CSFmobilized cells (G-DLI) vs conventional apheresis peripheral blood leukocytes (C-DLI). The reasons to administer multiple DLI included relapse of disease and incomplete donor chimerism. DLIs were discontinued when patients had no signs of malignant disease, had achieved improvement in the chimerism or when there were no more cells to administer. There was no standard aliquoting of G-CSF-mobilized products for cryopreservation, but cells were generally frozen in bags of between 10 to 100 million CD3 cells/kg recipient BW (according to cell availability). Various statistical methods were used to examine the above associations. For categorical factors such as HLA match, immunosuppressives at DLI, chemotherapy before DLI, whether cells were fresh or thawed at DLI and use of G-CSF-mobilized cells, w 2 test (or Fisher's exact test) and log-rank test were used; whereas for continuous variables, such as number of CD3 þ cells infused, nonparametric signed-rank test was used. Predicted OS and PFS were calculated according to the Kaplan-Meier method. Multivaraite Cox regression was also used in the survival analysis. All statistical analyses were performed using statistical software SAS version 9.2 or higher, SAS Institute Inc., Cary, NC, USA. The significance level being used was 0.05.
RESULTS

Patient characteristics
In total, 108 DLIs were administered to 67 patients. In total, 34 of 67 patients received single DLIs, 26 had 2 DLIs, 6 had 3 DLIs 1 had 4 DLIs (median number of DLIs was one). A total of 6 of 33 patients with two or more DLIs received their second within 30 days of the first DLI and 12/33 received a second DLI within 60 days of their first. With few exceptions subsequent DLIs were of greater numbers of cells (generally 3-10-fold larger CD3 cell numbers in last infusions than in initial DLIs). In all, 18 patients received a total of 32 G-CSF-mobilized DLIs (G-DLI) and 52 received a total of 76 C-DLI. Three received both G-DLI and C-DLI, all with C-DLI as last DLI. Of the 67 patients, 50 received C-DLI for their first dose, and 17 had G-DLI. For the 50 patients initially receiving C-DLI, 22 (44%) required a second DLI; whereas for the 17 G-DLI patients, 11 (64.7%) required a second DLI. The probabilities of a patient receiving a first DLI requiring a second one are NS different between the two groups (C-DLI vs G-DLI; Fisher's exact test P-value ¼ 0.1684).
All other analysis presented here was from the last DLI. However, we have also performed analysis from the first DLI (not shown but similar results to those presented below). Given that last DLIs were generally largest and thus expected to have had the greatest impact on results, their analysis is discussed here. Characteristics and some clinical measures related to the last DLI are described in Table 1 . Of the 67 patients, 15 had G-DLI as the last DLI and 52 C-DLI. DLIs were administered for relapse or residual disease in 57 patients, and because of poor engraftment in 10. Of these 10 patients, 3 received DLI for graft failure (o10% donor cells) and 7 for low chimerism.
In total, 46 of the 67 patients were under treatment for AML, or myelodysplastic syndrome. In all, 11 of these received G-DLI for their last DLI and 35 C-DLI. In all, 8 received DLI for poor engraftment and 38 patients for disease relapse or progression. OS Clinical outcomes are described in Table 2 . In total, 47 of 67 (70.1%) patients have died. The death rates for the G-DLI and Table 2 . Clinical outcomes related to the last DLI (percentages are all column percentages) Figure 1a , and for the G-DLI and C-DLI groups in Figure 1b . Patients receiving DLI for relapsed or residual malignant disease (that is, excluding 10 treated for poor graft function) showed similar OS in the G-DLI and C-DLI groups (log-rank test P ¼ 0.2079). Death was malignant disease related in 40 out of 47 (85.1%) patients, (range 3-793 and median 137 days after last DLI). In all, 5 of 47 (10.6%) patients died of GVHD (48-80 days from last DLI). Two patients died of unrelated causes-one of a motor vehicle accident 1612 days post last DLI, and the other of unknown cause at 490 days.
Of 42 patients receiving chemotherapy in the 90 days before last DLI, 35 died and 7 survived. Of 25 patients not treated with chemotherapy in this period, 12 died (difference by Fisher's exact test P ¼ 0.0049). OS was significantly higher in patients not receiving chemotherapy 90 before their DLI (log-rank test P ¼ 0.0119). Other pre-DLI factors being checked (using log-rank test) for the OS were: type of conditioning before BMT, donor type, HLA-match grade, use of immunosuppressive medication at time of DLI, whether the infusion for relapsed disease or poor engraftment, type of DLI cells, dose of DLI received (dichotomized, with 17/67 patients p10 Â 10 6 CD3 cells/kg BW and 50 receiving 410 Â 10 6 CD3 cells/kg BW), and whether the patient had developed relapse before the first DLI. However, none of those factors was statistically significant. Our findings in the log-rank tests have been confirmed by a multivariate Cox proportional hazard regression model: the difference between G-DLI and C-DLI was still NS (P ¼ 0.5049) and administration of chemotherapy in the 90 day period before last DLI was still significant (P ¼ 0.0212).
In AML/myelodysplastic syndrome patients median survival time was 210 days (range 3-2436 days). Again, the OS days were NS different between the G-DLI and C-DLI groups (log-rank test P ¼ 0.1876).
PFS
In total, 53 of 67 patients progressed after their last DLI. The rate of progression of disease after DLI was 11/15 (73.3%) for the G-DLI group and 42/52 (80.7%) in the C-DLI group. Median time to progression after last DLI was 81 days (range 1-2436 days) for all patients, and similar for the G-DLI group and C-DLI groups by logrank test (P ¼ 0.8861). Kaplan-Meier curve for PFS is shown in Figure 2a .
As for OS analysis, log-rank tests suggested independence of PFS from all pre-DLI factors. In the Cox regression model, the DLI group (G-DLI vs C-DLI) was still NS (P ¼ 0.8009; neither was any of the controlling factors-results not shown). During the year of follow-up after last DLIs, there was no progression of malignant disease in 4 of 15 patients (27%) receiving a last G-DLI, and 14 of 52 (27%) receiving C-DLI (Fisher's exact test-NS).
Of the 46 AML/myelodysplastic syndrome patients, median PFS time was 82 days, 124 days in the G-DLI group of 11 patients and 81 days in the 35 patient C-DLI group (Kaplan-Meier shown in Figure 2b , log-rank test P ¼ 0.4563).
GVHD and chimerism
In total, 42 patients developed GVHD; time from last DLI to GVHD (range 1-907 days) was a median of 32 days. In all, 9 out of 15 (60%) patients in the G-DLI group and 33/52 (63.5%) in the C-DLI group had GVHD. GVHD rates were NS different in these groups (Fisher's exact test P ¼ 1, log-rank test P ¼ 0.4214). Development of GVHD has been shown (by log-rank test) to be independent of all Role of G-CSF mobilized DLI KKS Abbi et al other pre-DLI factors except the administration of chemotherapy in the 90 days before DLI (P ¼ 0.0541), and HLA-match grade (P ¼ 0.0146). These findings have been confirmed by the multivariate Cox regression analysis. An analysis of events after DLI was carried out to determine the relative risk of GVHD vs death from non-GVHD causes. The cumulative incidence function of GVHD and death without GVHD showed that GVHD is the dominant risk.
Post-DLI improvement in donor chimerism was studied in patients in whom pre-DLI chimerism was o75% donor (17/67 patients). Chimerism was scored as significantly improved only if it increased by 20% or more within 100 days of initial DLI. Improved chimerism developed in 3/5 (60%) patients in the G-DLI group and in 8/12 (66.7%) in the C-DLI group (no significant difference, Fisher's exact test P ¼ 1). Improvement in chimerism was better in patients with use of immunosuppressive at time of DLI but the results were only marginally significant due to the small sample size (Fisher's exact test P ¼ 0.0934). Chimerism improvement was independent of all other pre-DLI factors.
DISCUSSION
Our data set of varied patients and donors suggests that OS and PFS were not shown related to the size of DLI dose. There is considerable controversy regarding the effect of initial dose on survival. In Guglielmi et al.
16 study doses 40.2 Â 10 14 cells/kg increased morbidity and mortality without adding any significant benefit to survival. Response to DLI has not always been associated with GVHD, suggesting that the GVL effect may be independent of the clinical development of GVHD. 6, 17 Starting the infusions of donor cells at low cell numbers followed by escalating doses as required (that is, until achievement of response or development of GVHD) may reduce the incidence and severity of GVHD, while preserving the GVL effect. 13, 18 In our study, C-DLI was generally given after additional chemotherapy, whereas G-DLI was more often not. This difference may have been due to the ease and availability of G-DLI, in contrast to C-DLI, a therapy requiring significant preparation and revalidation of the donor.
Other factors shown to be predictive of response in studies include T-cell depletion at the time of transplant, 6 longer interval between transplant and diagnosis of relapse 19 and the presence of donor chimerism at time of DLI. 20 The major drawback of DLI is GVHD, with an overall incidence between 10 and 50%. 21, 22 Dazzi et al. 21 data suggested that patient/donor sex mismatch, CMV seropositivity, T-cell depletion at transplant and advanced patient age are prognostic factors associated with aGVHD in CML patients treated with DLI. Other data suggest that two factors predict both aGVHD and chronic GVHD: the infusion of male recipients with lymphocytes from a female donor and the interval between transplant and last DLI, but only the first remained significant at multivariate analysis. Lymphocyte dose did not influence the incidence of GVHD. 23 The role of the pre-DLI donor chimerism in predicting outcomes after DLI is more controversial. In patients who relapsed after T-cell-depleted HCT, inferior remission rates (15 vs 77%) were seen for those with o40% as compared with 440% donor T lymphocytes at the time of DLI. 20 Other authors have not observed any chimerism influence on attaining CR after DLI 24 or in general outcomes for patients with multiple myeloma. 25 Many studies have demonstrated that in vivo G-CSF may modify the function of lymphocytes in peripheral blood harvests. 26, 27 G-CSF induces mobilization of DC2 in humans that increase the availability of DC2 in peripheral lymphoid organs, leading to the presentation of self peptides and Th2 polarization in the donor. 28 In several experimental models, donor Th2 cells have a decreased potential to induce aGVHD. [29] [30] [31] [32] [33] [34] G-CSF-mobilized grafts have been associated with reduced severity of aGVHD apparently via disruption of cytokine cascades involved in the development of aGVHD. Importantly, however, G-CSF-mobilized grafts maintain their GVL effects through a perforin-dependent pathway. 35 After in vivo administration of G-CSF, human and murine peripheral blood T cells have shown reduced cytotoxic activity and proliferative response upon in vitro stimulation. 36 Monocytes of peripheral blood from G-CSF-mobilized human donors have also been shown to suppress T-cell allo-reactivity. This suppression may occur through an IL-10-dependent mechanism, downregulation of CD28/B7(CD80 and CD86) co-stimulatory molecules signals and/or through the inhibition of IL-12 and TNF-alpha release. 26, 37 It may be asked: 'Why did certain patients in our series have G-DLI products available whereas others did not?' The decision to infuse all or some of available G-CSF-mobilized cells at the time of transplant is left to the discretion of the treating physician at our center, thus practices may have varied according to physician preference or inclination. Data suggesting increased GVHD associated with higher CD34 þ cell doses were certainly available and conditioned some such decisions. The use of unrelated donors and doubts regarding the ease of availability of the donor for subsequent DLI may in some cases have prompted cryopreservation of a portion of G-mobilized cells. This may in some measure account for the larger number of URD products among the G-DLI patients.
In our study, all the G-DLIs were cryopreserved DLIs whereas half of the C-DLIs were cryopreserved and half were fresh. The impact of cryopreservation on graft content and clinical outcomes for DLI has not been formally studied. If the observation by Eckardt et al. 38 that cryopreservation may ameliorate GVHD is valid, one would be concerned that the GVL effect being sought by DLI could be amelioriated as well.
We have analyzed four endpoints subsequent to DLI. OS, PFS, development of GVHD and improvement in chimerism are all similar in the G-DLI and C-DLI groups. This suggests that the use of G-CSF-mobilized donor cells in lieu of conventional peripheral blood-derived donor lymphocytes provides equivalent results in terms of PFS and OS, and clinical parameters associated with donor-host allorectivity. It must be acknowledged that the number of patients available for assessment of survivorship or of clinical disease response is small. Therefore, we have analyzed two other parameters that may logically be hypothesized to be dependent on allo-reactivity of the donor cells. GVHD is well recognized to develop after DLI, and may reasonably be seen to result from such therapy when occurring weeks to months after the infusion. Similarly, poor donor chimerism is known to respond to DLI, thus when chimerism improves following such infusion, an association may logically be made to the DLI. These two parameters therefore, we suggest, provide additional useful endpoints with which to judge the immunological activity of DLI. Notwithstanding this concern, our observations suggest practical conclusions regarding management of the difficult and all too frequent issue of post-transplant relapse of malignant disease. Where G-CSF-mobilized cells are available, they may be given in lieu of resting conventional peripheral blood lymphocytes with reasonable expectations for pro-engraftment and antitumor therapeutic activity.
